{"doi":"10.1002/oby.24289","title":"Lifestyle behavioral weight‐loss treatment for binge‐eating disorder in patients with obesity: where's the harm?","abstract":"OBJECTIVE: Although recent rigorous trials have demonstrated effectiveness of behaviorally based weight-loss treatment (BBWLT) for binge-eating disorder (BED) with coexisting obesity, concerns have been raised that such interventions are contraindicated because they might trigger or exacerbate eating disorder (ED) psychopathology. This secondary analysis of a BBWLT trial examined heterogeneity of outcomes to identify the frequency that individuals experienced increased symptoms. METHODS: One hundred ninety-one participants with BED and obesity in a 6-month BBWLT trial were assessed for binge eating, ED psychopathology, and weight at baseline, at posttreatment, and at a 12-month follow-up after treatment (i.e., 18 months after baseline). Changes were examined at the individual level to identify cases of any increased features. RESULTS: At posttreatment, 95.3% (n = 162) of participants reported decreased binge-eating frequency, and 87.6% (n = 149) reported decreased ED psychopathology scores. At the 12-month follow-up, 97.1% (n = 135) reported decreased binge-eating frequency, and 93.0% (n = 120) reported decreased ED psychopathology scores. Inspection of the few instances of any increases revealed mostly small magnitudes. CONCLUSIONS: Frequency of cases with any increased symptoms of binge eating and/or ED psychopathology was quite low at posttreatment and at 1 year after ending BBWLT for BED and obesity. These participant-level findings add important clinical context regarding overall improvements with BBWLT for BED with obesity (large effect sizes) and challenge concerns that BBWLT exacerbates ED psychopathology.","journal":"Obesity","year":2025,"id":516658,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9548,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":301061,"name":"Valentina Ivezaj","orcid":"0000-0001-8760-8040","position":1,"is_corresponding":false},{"id":237456,"name":"Carlos M. Grilo","orcid":"0000-0003-0245-3444","position":2,"is_corresponding":false},{"id":1090445,"name":"Sydney Yurkow","orcid":"0000-0003-3569-4666","position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":null,"created_at":"2026-07-19T02:48:49.486328Z","pmid":"40342236","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}